Literature DB >> 18515459

Safety of therapeutic methylphenidate in adults: a systematic review of the evidence.

J Godfrey1.   

Abstract

Attention deficit hyperactivity disorder (ADHD) often persists into adulthood. Stimulant drugs, including methylphenidate, have showed efficacy in trials for ADHD in adults. Adult psychiatrists are likely to encounter increasing numbers of adult patients who may benefit from methylphenidate. A systematic review of the literature was made to examine the evidence on the safety of methylphenidate, when used therapeutically in adults. Twenty-six placebo-controlled trials were found, in which 811 adults received methylphenidate for ADHD and other conditions. In the short term, methylphenidate was well tolerated and no serious side effects were observed. There is little information on the long-term safety of methylphenidate in adults, although the number of serious adverse effects reported to regulatory authorities has, so far, been low. Methylphenidate is associated with a modest rise in blood pressure and heart rate. Surveys of stimulant use in US universities show that misuse of prescribed medication, for recreation or to enhance study, is fairly common although the level of harm that arises from this practice is unclear.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18515459     DOI: 10.1177/0269881108089809

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  25 in total

Review 1.  Can Doping be a Good Thing? Using Psychoactive Drugs to Facilitate Physical Activity Behaviour.

Authors:  Samuele Marcora
Journal:  Sports Med       Date:  2016-01       Impact factor: 11.136

Review 2.  Metabolomics of Methylphenidate and Ethylphenidate: Implications in Pharmacological and Toxicological Effects.

Authors:  Ricardo Jorge Dinis-Oliveira
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-02       Impact factor: 2.441

3.  Locus coeruleus neuronal activity correlates with behavioral response to acute and chronic doses of methylphenidate (Ritalin) in adolescent rats.

Authors:  Natasha Kharas; Cruz Reyes-Vazquez; Nachum Dafny
Journal:  J Neural Transm (Vienna)       Date:  2017-07-20       Impact factor: 3.575

4.  Should physicians prescribe cognitive enhancers to healthy individuals?

Authors:  Cynthia Forlini; Serge Gauthier; Eric Racine
Journal:  CMAJ       Date:  2012-12-17       Impact factor: 8.262

5.  Effects of Fatty Acid Amide Hydrolase (FAAH) Inhibitors in Non-Human Primate Models of Nicotine Reward and Relapse.

Authors:  Zuzana Justinova; Leigh V Panlilio; Guillermo Moreno-Sanz; Godfrey H Redhi; Alessia Auber; Maria E Secci; Paola Mascia; Tiziano Bandiera; Andrea Armirotti; Rosalia Bertorelli; Svetlana I Chefer; Chanel Barnes; Sevil Yasar; Daniele Piomelli; Steven R Goldberg
Journal:  Neuropsychopharmacology       Date:  2015-03-10       Impact factor: 7.853

6.  Lack of neuronal nitric oxide synthase results in attention deficit hyperactivity disorder-like behaviors in mice.

Authors:  Yudong Gao; Scott A Heldt
Journal:  Behav Neurosci       Date:  2015-02       Impact factor: 1.912

7.  The discriminative stimulus properties of methylphenidate in C57BL/6J mice.

Authors:  Robin W McGovern; Lawrence D Middaugh; Kennerly S Patrick; William C Griffin
Journal:  Behav Pharmacol       Date:  2011-02       Impact factor: 2.293

Review 8.  Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction.

Authors:  Leigh V Panlilio; Zuzana Justinova; Steven R Goldberg
Journal:  Pharmacol Ther       Date:  2013-01-16       Impact factor: 12.310

Review 9.  Treatment discontinuation with methylphenidate in adults with attention deficit hyperactivity disorder: a meta-analysis of randomized clinical trials.

Authors:  Xavier Castells; Ruth Cunill; Dolors Capellà
Journal:  Eur J Clin Pharmacol       Date:  2012-09-16       Impact factor: 2.953

10.  Safety and tolerability of flexible dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.

Authors:  Jan K Buitelaar; J Antoni Ramos-Quiroga; Miguel Casas; J J Sandra Kooij; Asko Niemelä; Eric Konofal; Joachim Dejonckheere; Bradford H Challis; Rossella Medori
Journal:  Neuropsychiatr Dis Treat       Date:  2009-09-15       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.